Lung Transplantation for Cystic Fibrosis

Pilewski, Joseph M.

doi:10.1007/978-3-030-42382-7_12

Cited by 1 publication

(2 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the previous treatments, other alternatives for eliminating P. aeruginosa infections have been investigated, including inhaled gallium and sodium nitrite (Table 6) [157,300,301]. A previous preclinical study showed that gallium works by decreasing bacterial iron (Fe) uptake and interfering with Fe signaling [302].…”

Section: Strategies Targeting P Aeruginosa Iron Acquisition Systemsmentioning

confidence: 99%

“…In addition to gallium, another phase I/II study assessed the safety of inhaled sodium nitrite in 35 adults with CF and chronic Pseudomonas infections to reduce the burden of P. aeruginosa NCT02694393) [301]. Sodium nitrite was effective in eliminating P. aeruginosa within the lung of CF-infected patients by increasing the susceptibility of P. aeruginosa to antibiotics [304,305].…”

Section: Strategies Targeting P Aeruginosa Iron Acquisition Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials

et al. 2023

View full text Add to dashboard Cite

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen that causes high morbidity and mortality in cystic fibrosis (CF) and immunocompromised patients, including patients with ventilator-associated pneumonia (VAP), severely burned patients, and patients with surgical wounds. Due to the intrinsic and extrinsic antibiotic resistance mechanisms, the ability to produce several cell-associated and extracellular virulence factors, and the capacity to adapt to several environmental conditions, eradicating P. aeruginosa within infected patients is difficult. Pseudomonas aeruginosa is one of the six multi-drug-resistant pathogens (ESKAPE) considered by the World Health Organization (WHO) as an entire group for which the development of novel antibiotics is urgently needed. In the United States (US) and within the last several years, P. aeruginosa caused 27% of deaths and approximately USD 767 million annually in health-care costs. Several P. aeruginosa therapies, including new antimicrobial agents, derivatives of existing antibiotics, novel antimicrobial agents such as bacteriophages and their chelators, potential vaccines targeting specific virulence factors, and immunotherapies have been developed. Within the last 2–3 decades, the efficacy of these different treatments was tested in clinical and preclinical trials. Despite these trials, no P. aeruginosa treatment is currently approved or available. In this review, we examined several of these clinicals, specifically those designed to combat P. aeruginosa infections in CF patients, patients with P. aeruginosa VAP, and P. aeruginosa–infected burn patients.

show abstract

Section: Strategies Targeting P Aeruginosa Iron Acquisition Systemsmentioning

confidence: 99%

Section: Strategies Targeting P Aeruginosa Iron Acquisition Systemsmentioning

confidence: 99%

Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials

et al. 2023

View full text Add to dashboard Cite

show abstract

Lung Transplantation for Cystic Fibrosis

Cited by 1 publication

References 102 publications

Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials

Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials

Contact Info

Product

Resources

About